Vaxil Bio Ltd. Stock price

Equities

VXL

CA92243L1076

Biotechnology & Medical Research

Market Closed - Toronto S.E. 03:07:21 2024-03-27 pm EDT 5-day change 1st Jan Change
0.015 CAD 0.00% Intraday chart for Vaxil Bio Ltd. 0.00% -40.00%
Sales 2021 - Sales 2022 - Capitalization 2.74M 3.71M
Net income 2021 - 0 Net income 2022 - 0 EV / Sales 2021 -
Net cash position 2021 2.24M 3.04M Net cash position 2022 1.51M 2.05M EV / Sales 2022 -
P/E ratio 2021
-10.4 x
P/E ratio 2022
-4.69 x
Employees -
Yield 2021 *
-
Yield 2022
-
Free-Float 91.83%
More Fundamentals * Assessed data
Dynamic Chart
Current month-40.00%
1 month-40.00%
Current year-40.00%
More quotes
1 week
0.01
Extreme 0.01
0.02
1 month
0.01
Extreme 0.01
0.03
Current year
0.01
Extreme 0.01
0.03
1 year
0.01
Extreme 0.01
0.04
3 years
0.01
Extreme 0.01
0.16
5 years
0.00
Extreme 0
0.77
10 years
0.00
Extreme 0
0.77
More quotes
Managers TitleAgeSince
Chief Executive Officer 52 16-02-29
Director of Finance/CFO 72 23-07-30
Chief Tech/Sci/R&D Officer - -
Members of the board TitleAgeSince
Director/Board Member - 17-12-04
Chief Executive Officer 52 16-02-29
Director/Board Member - 17-12-04
More insiders
Date Price Change Volume
24-03-27 0.015 0.00% 319,000
24-03-26 0.015 +50.00% 246,024
24-03-25 0.01 0.00% 22,000
24-03-22 0.01 -33.33% 13,613
24-03-21 0.015 +50.00% 4,000

Delayed Quote Toronto S.E., March 27, 2024 at 03:07 pm EDT

More quotes
Vaxil Bio Ltd. is a Canada-based biotechnology company. The Company is focused on a drug discovery and development platform based on Signal Peptides (SPs) which the Company deploys to fight infectious diseases and cancer. The Company’s most advanced product, ImMucin, a MUC1 SP-derived vaccine, completed a Phase I/II clinical trial in multiple myeloma. The Company also has a SP-based COVID-19 vaccine candidate and a SP-based tuberculosis vaccine / treatment candidate. In addition, The Company has mAb candidates for the treatment of oncology and infectious diseases to be used alone, and in combination with other treatments. It has also initiated a pre-clinical program for a drug delivery polymer that targets high affinity E-selectin (P-Esbp), which the Company licensed for development and commercialization from BGN Technologies. It exploits the properties of SP domains on crucial proteins to develop targeted therapies against cancer targets and infectious disease pathogens.
More about the company
  1. Stock
  2. Equities
  3. Stock Vaxil Bio Ltd. - Toronto S.E.